Neuronetics Stock Forecast, Price & News

Neuronetics (NASDAQ:STIM) Frequently Asked Questions

Is Neuronetics a buy right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Neuronetics in the last twelve months. There are currently 2 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Neuronetics stock.
View analyst ratings for Neuronetics or view top-rated stocks.

How has Neuronetics' stock price been impacted by Coronavirus?

Neuronetics' stock was trading at $2.07 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, STIM stock has increased by 90.8% and is now trading at $3.95.
View which stocks have been most impacted by COVID-19.

Are investors shorting Neuronetics?

Neuronetics saw a drop in short interest in October. As of October 29th, there was short interest totaling 979,800 shares, a drop of 18.4% from the October 14th total of 1,200,000 shares. Based on an average trading volume of 419,100 shares, the short-interest ratio is presently 2.3 days. Currently, 4.0% of the company's stock are short sold.
View Neuronetics' Short Interest.

When is Neuronetics' next earnings date?

Neuronetics is scheduled to release its next quarterly earnings announcement on Tuesday, March 1st 2022.
View our earnings forecast for Neuronetics.

How were Neuronetics' earnings last quarter?

Neuronetics, Inc. (NASDAQ:STIM) announced its quarterly earnings results on Tuesday, November, 9th. The company reported ($0.31) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.28) by $0.03. Neuronetics had a negative net margin of 48.71% and a negative trailing twelve-month return on equity of 34.48%. During the same quarter in the previous year, the firm posted ($0.18) EPS.
View Neuronetics' earnings history.

What guidance has Neuronetics issued on next quarter's earnings?

Neuronetics issued an update on its FY 2021 earnings guidance on Tuesday, November, 30th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $53.30 million-$54.30 million, compared to the consensus revenue estimate of $55.83 million.

What price target have analysts set for STIM?

5 brokerages have issued 12-month price targets for Neuronetics' stock. Their forecasts range from $12.00 to $21.00. On average, they expect Neuronetics' stock price to reach $15.00 in the next twelve months. This suggests a possible upside of 279.7% from the stock's current price.
View analysts' price targets for Neuronetics or view top-rated stocks among Wall Street analysts.

Who are Neuronetics' key executives?

Neuronetics' management team includes the following people:

• Keith J. Sullivan, President, Chief Executive Officer & Director (LinkedIn Profile)
• Stephen Furlong, Chief Financial Officer, Treasurer & Senior VP (LinkedIn Profile)
• Cory Anderson, VP-Clinical Affairs & Medical Operations
• W. Andrew Macan, Secretary, Chief Compliance Officer & Senior VP
• Todd Cushman, Vice President-Business Development

Who are some of Neuronetics' key competitors?

Some companies that are related to Neuronetics include Utah Medical Products (UTMD), Assure (ARHH), Tactile Systems Technology (TCMD), Beyond Air (XAIR), InfuSystem (INFU), AVITA Medical (RCEL), ClearPoint Neuro (CLPT), PAVmed (PAVM), Westaim (WEDXF), Asensus Surgical (ASXC), Lucid Diagnostics (LUCD), Retractable Technologies (RVP), DarioHealth (DRIO), Co-Diagnostics (CODX) and NeuroPace (NPCE).
View all of STIM's competitors.

What other stocks do shareholders of Neuronetics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Neuronetics investors own include SCYNEXIS (SCYX), Inovio Pharmaceuticals (INO), Novavax (NVAX), Gilead Sciences (GILD), iBio (IBIO), Onconova Therapeutics (ONTX), Pfizer (PFE), Tonix Pharmaceuticals (TNXP), Vaxart (VXRT) and Acasti Pharma (ACST).

When did Neuronetics IPO?

(STIM) raised $75 million in an IPO on Thursday, June 28th 2018. The company issued 5,000,000 shares at $14.00-$16.00 per share. Piper Jaffray and William Blair acted as the underwriters for the IPO and Canaccord Genuity, BTIG and JMP Securities were co-managers.

What is Neuronetics' stock symbol?

Neuronetics trades on the NASDAQ under the ticker symbol "STIM."

Who are Neuronetics' major shareholders?

Neuronetics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Cannell Capital LLC (7.91%), Schroder Investment Management Group (6.70%), BlackRock Inc. (5.97%), Granahan Investment Management Inc. MA (3.34%), First Washington CORP (1.75%) and Two Sigma Advisers LP (1.32%). Company insiders that own Neuronetics stock include Brian E Farley, Bruce Joseph Shook, Daniel Guthrie, Gregory Harper, Keith J Sullivan, Paul Liberman, Robert Cascella, Sheryl L Conley, Stephen Furlong and William Andrew Macan.
View institutional ownership trends for Neuronetics.

Which institutional investors are selling Neuronetics stock?

STIM stock was sold by a variety of institutional investors in the last quarter, including Invesco Ltd., Assenagon Asset Management S.A., Geode Capital Management LLC, California State Teachers Retirement System, New York State Common Retirement Fund, and Jane Street Group LLC. Company insiders that have sold Neuronetics company stock in the last year include Bruce Joseph Shook, Gregory Harper, Keith J Sullivan, Paul Liberman, Sheryl L Conley, Stephen Furlong, and William Andrew Macan.
View insider buying and selling activity for Neuronetics or view top insider-selling stocks.

Which institutional investors are buying Neuronetics stock?

STIM stock was bought by a variety of institutional investors in the last quarter, including Schroder Investment Management Group, Cannell Capital LLC, First Washington CORP, Two Sigma Advisers LP, Granahan Investment Management Inc. MA, Two Sigma Investments LP, Morgan Stanley, and Paradigm Capital Management Inc. NY. Company insiders that have bought Neuronetics stock in the last two years include Brian E Farley, Daniel Guthrie, Gregory Harper, Robert Cascella, Stephen Furlong, and William Andrew Macan.
View insider buying and selling activity for Neuronetics or or view top insider-buying stocks.

How do I buy shares of Neuronetics?

Shares of STIM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Neuronetics' stock price today?

One share of STIM stock can currently be purchased for approximately $3.95.

How much money does Neuronetics make?

Neuronetics has a market capitalization of $104.15 million and generates $49.24 million in revenue each year. The company earns $-27.45 million in net income (profit) each year or ($1.10) on an earnings per share basis.

How many employees does Neuronetics have?

Neuronetics employs 126 workers across the globe.

What is Neuronetics' official website?

The official website for Neuronetics is www.neurostar.com.

Where are Neuronetics' headquarters?

Neuronetics is headquartered at 3222 PHOENIXVILLE PIKE, MALVERN PA, 19355.

How can I contact Neuronetics?

Neuronetics' mailing address is 3222 PHOENIXVILLE PIKE, MALVERN PA, 19355. The company can be reached via phone at (610) 640-4202, via email at [email protected], or via fax at 610-640-4206.